4201. Accelerating Cardiac Amyloidosis Diagnosis With AI: Implementation Insights From Mayo Clinic

Innovation Stage, #2064
Sponsored by AstraZeneca

This session explores exciting initiatives by Mayo Clinic to develop and deploy AI-assisted ECG and echo for enabling early detection of cardiac amyloidosis and generating structured clinical workflows for treatment. The presentation will delve into considerations for implementation, partnership and scalability, with the goal of encouraging practitioners in their own initiatives.

Speaker:

Patricia A. Pellikka, MD
The Betty Knight Scripps Professor of Cardiovascular Disease Clinical Research
President, Mayo Clinic Officers and Councilors
Consultant, Department of Cardiovascular Medicine
Editor-in-Chief, Journal of the American Society of Echocardiography
Mayo Clinic
Rochester, MN

4202. She Says/He Says: HFrEF Patient Management in the Contemporary Era of GDMT: A Friendly Debate

Innovation Stage, #2064
Sponsored by ZOLL

In this sure-to-be lively session, Dr. Hrobowski-Blackman, an advanced heart failure and transplant cardiologist, and Dr. Tomassoni, an electrophysiologist, will debate approaches to managing HFrEF patients, to include recent data on sudden cardiac arrest risk.

Speakers:

Tara Hrobowski-Blackman, MD
HCA Florida Largo Hospital
Largo, FL

Gery Tomassoni, MD, FACC, FHRS
Baptist Health Lexington
Lexington, KY

4203. Pivotal and Cardiac Structure and Function Outcomes With CAMZYOS® in Patients With Symptomatic NYHA Class II–III Obstructive HCM

Innovation Stage, #2064
Sponsored by Bristol Myers Squibb

Join this session to review data from pivotal and long-term data on the impact of CAMZYOS on cardiac structure and function outcomes in adult patients with symptomatic NYHA Class II-III obstructive.

Speaker:

Mariko Harper, MD, FACC
Medical Director,
Hypertrophic Cardiomyopathy Center
Virgina Mason Franciscan Health System

4204. A Clinician's Perspective: Holistic Approach to Managing PKP2-Associated Arrhythmogenic Cardiomyopathy

Innovation Stage, #2064
Sponsored by Lexeo Therapeutics

Join us for a dynamic fireside chat that explores how understanding a patient's lived experience can impactfully advance care and address unmet treatment needs in plakophilin‑2 arrhythmogenic cardiomyopathy (PKP2‑ACM). Moderated by the CEO of the SADS Foundation, this fireside chat will bring together the voices of individuals living with PKP2‑ACM and the clinicians who care for them to discuss the importance of integrating genetic testing into a patient's diagnostic journey and to highlight both perspectives on evolving PKP2‑ACM therapies.

Speakers:

Walker Frahm
Chief Executive Officer
SADS Foundation

Genevie Echols
Family Support, Advocacy, & Research Director
SADS Foundation

Daniel Judge, MD, FACC, FHFSA
Professor of Medicine/Cardiology
Medical University of South Carolina
Edwin W. and Teresa H. Rogers Endowed Professor
Fellowship Program Director, Cardiology
Director of Cardiovascular Genetics
Section of Advanced Heart Failure & Transplant

4205. AI-Driven Echocardiography: From Insight to Impact

Innovation Stage, #2064
Sponsored by Siemens Healthineers

Join us for a live demonstration of echocardiography AI in action. Practical AI is reshaping echocardiography—improving efficiency, reducing ergonomic strain, standardizing care, and expanding patient access. Learn how AI-assisted view classification paired with automated measurements can revolutionize the traditional echo exam. Join us for a live scanning demonstration and a discussion of the real-world workflow consideration that matter most in daily practice.

Speakers:

Robert Burke, MD, FACC, FASE, FSCA

Alicia Armour, MA, ACS, RDCS, FASE

4206. The Potential to Reduce HF Readmissions to Single Digits

Innovation Stage, #2064
Sponsored by ZOLL

In this session Chelsea Christensen will discuss how the use of ZOLL's Heart Failure Management System (HFMS) has assisted in reducing 30 day HF readmission rates to single digits.

Speaker:

Chelsea E. Christensen, PA-C
Sentara Virginia Beach General Hospital

4207. The Future of TAVR & Evolut in Low-Risk Patients

Innovation Stage, #2064
Sponsored by Medtronic

Evolut demonstrates a sustained commitment to clinical innovation by addressing the increasingly complex and evolving requirements of valve selection for patients undergoing TAVR. Explore clinical insights on the use of Evolut TAVR in low-risk patients and examine how AI-driven pre-procedural planning can enhance procedural decision-making.

4208. On ALERT: Using AI-Powered EHR Alerts to Fast Track Evidence Based Care For VHD

Innovation Stage, #2064
Sponsored by Medtronic

Overview of the ALERT trial to evaluate how automated notifications support the identification and evaluation of patients with severe aortic stenosis and mitral regurgitation. The trial aims to address the significant gaps in the recognition and management of severe AS and MR which if left untreated leads to increased morbidity and mortality.

Speakers:

Wayne Batchelor, MD, MHS, MBA
President, Medicine Service Line
Inova Health System

Brian R. Lindman, MD, MSc, FACC
Medical Director, Structural Heart and Valve Center
Associate Professor of Medicine
Vanderbilt University Medical Center

4209. Decoding a Silent Threat: Uncovering Aldosterone's Impact on Hypertension and Cardiovascular Morbidity

Innovation Stage, #2064
Sponsored by AstraZeneca

Nearly half of U.S. adults with hypertension (HTN) have uncontrolled blood pressure, despite taking multiple antihypertensive medications. This persistent challenge greatly increases their risk of cardiovascular and kidney complications, as well as mortality. We'll explore the often overlooked role of aldosterone as a key pathophysiological driver of HTN, which raises the question — could novel treatments targeting aldosterone production be warranted for patients with HTN who remain uncontrolled?

Speaker:

Ankheet Bhatt, MD, MBA, ScM

4210. Reframing Cardiovascular Risk Assessment: The Role of CCTA and Plaque Analysis

Innovation Stage, #2064
Sponsored by Heartflow

After participating in this session, attendees will be able to:

• Describe how quantitative coronary plaque assessment informs cardiovascular risk assessment
• Explain the role of CCTA and Heartflow Plaque Analysis in moving beyond traditional risk calculators for more precise risk stratification
• Discuss the intersection of advanced imaging with the new cholesterol guidelines, including implications for identifying patients who may benefit from earlier or intensified therapy

Speakers:

Ron Blankstein, MD
Harvard Medical School
Brigham and Women's Hospital
Boston, MA

Seth Martin, MD
Yale School of Medicine
New Haven, CT

4211. Treating Hyperkalemia: A Critical Step in Heart Failure Management

Innovation Stage, #2064
Sponsored by AstraZeneca

This session will explore the risk of hyperkalemia (HK) among patients with heart failure and its impact on the use of RAASi or MRA therapies. The discussion will highlight guideline recommendations and clinical evidence supporting potassium binders as effective options to treat HK. Treating HK may enable the continuation of RAASi/MRA therapy. A case-based example will illustrate practical integration into patient care.